Aduhelm (aducanumab-avwa)

news

Biogen refocuses its Alzheimer’s strategy

2 February 2024 | By Catherine Eckford (European Pharmaceutical Review)

Part of Biogen’s prioritisation of its portfolio includes focusing on the advancement of its leading anti-amyloid beta Alzheimer’s treatment, LEQEMBI® (lecanemab-irmb).

article

Treating Alzheimer’s: regulatory hurdles in an anti-amyloid revolution

3 August 2023 | By Gareth Morgan (Pinsent Masons)

In this article, Gareth Morgan, a life sciences partner at Pinsent Masons discusses how Leqembi validates the anti-amyloid approach for treating Alzheimer’s, and whether its recent regulatory authorisations could support fast-tracking approvals of other promising Alzheimer’s therapies.

news

Is Aduhelm^® of benefit to Alzheimer’s patients long-term?

17 March 2022 | By Hannah Balfour (European Pharmaceutical Review)

New data shows that patients taking Aduhelm® (aducanumab-avwa) had significant reductions in tau and amyloid beta after nearly 2.5 years.

news

EMA’s human medicines committee (CHMP) Feb meeting highlights

28 February 2022 | By European Pharmaceutical Review

Highlights of the February 2022 meeting of EMA’s human medicines committee (CHMP) include the recommendation of 13 medicines for approval, along with updates to other drugs and COVID-19 vaccines.

news

Alzheimer’s drug Aduhelm™ authorised in US under accelerated approval

8 June 2021 | By Hannah Balfour (European Pharmaceutical Review)

Aduhelm™ (aducanumab-avwa) is the first new treatment approved for Alzheimer’s since 2003 and the first therapy to target the fundamental pathophysiology of the disease – amyloid plaques.